IM Cannabis (IMCC) Receivables (2019 - 2026)

IM Cannabis (IMCC) posted quarterly Receivables of $5.2 million for Q1 2026, down 34.12% quarter-over-quarter from $7.9 million in Q4 2025.

IM Cannabis (IMCC) Receivables (2019 - 2026) Analysis & Trends

IM Cannabis' Receivables history runs 8 years deep, the most recent figure standing at $5.2 million for Q1 2026.

In Q1 2026, Receivables changed N/A year-over-year to $5.2 million; the TTM figure through Mar 2026 stood at $5.2 million (changed N/A YoY), while the FY2025 annual figure was $7.9 million, down 22.86% from the prior year.
Receivables for Q1 2026 stood at $5.2 million, down from $7.9 million in the prior quarter.
The five-year high for Receivables was $24.2 million in Q1 2022, with the low at $5.2 million in Q1 2026.
The 5-year median for Receivables is $9.4 million (2023), against an average of $10.6 million.
The sharpest annual moves came in 2023 and 2024: Receivables slumped 69.8% in 2023, then jumped 59.69% in 2024.
IM Cannabis' Receivables stood at $6.5 million in 2022, then declined by 3.52% to $6.3 million in 2023, then surged by 59.69% to $10.1 million in 2024, then declined by 21.29% to $7.9 million in 2025, then tumbled by 34.12% to $5.2 million in 2026.
Business Quant data shows IMCC's Receivables at $5.2 million in Q1 2026, $7.9 million in Q4 2025, and $8.2 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Haleon	43.83 Bn	42.86 Bn	-	3.07 Bn
2	Teva Pharmaceutical Industries	42.87 Bn	39.22 Bn	2.15 Bn	3.49 Bn
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	1.57 Bn
4	Takeda Pharmaceutical	28.55 Bn	22.75 Bn	5.10 Bn	5.84 Bn
5	United Therapeutics	22.08 Bn	19.42 Bn	683.80 Mn	310.30 Mn
6	Viatris	18.73 Bn	17.84 Bn	1.46 Bn	3.67 Bn
7	Neurocrine Biosciences	15.44 Bn	15.05 Bn	935.80 Mn	887.00 Mn
8	Elanco Animal Health	11.75 Bn	11.22 Bn	798.00 Mn	1.15 Bn
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	1.08 Bn
10	IM Cannabis	554,496.00	-614,474.17	1.09 Mn	4.96 Mn

Download Data